川北医学院学报2017，Vol.32Issue(1)：53-56,4.DOI:10.3969/j.issn.1005-3697.2017.01.015
Ki-67预测乳腺癌对新辅助化疗反应的价值
Ki-67 predicting the response to neoadjuvant chemotherapy in breast cancer patients
摘要
Abstract
Objective:To assess the potential value of Ki-67 in predicting the response to neoadjuvant chemotherapy in breast cancer patients.Methods:One hundred and fourteen breast cancer patients who underwent neoadjuvant therapy prior to surgery between 2006 and 2013.Clinical and immunohistochemical factors preoperative were analyzed to determine their correlation with the response to neoadjuvant chemotherapy.Results:Four patients (4.5％) achieved clinical complete response,86 patients (75.4％) in clinical partial response,24 patients (21.2％) in clinical stable disease.Pathological complete response (pCR) was observed in 26 patients (22.8 ％).Ki-67 was the only independent predictor of pCR (P =0.027).ROC analysis showed 25％ of Ki-67 would be a reasonable value for predicting the response to chemotherapy.Conclusion:Ki-67 could be an effective item for indicating breast cancer's reaction to neoadjuvant chemotherapy,and a reasonable cut-point value for Ki-67 expression level would be 25％.关键词
乳腺癌/Ki-67/新辅助化疗Key words
Breast neoplasma/Ki-67 antigen/Neoadjuvant therapy分类
医药卫生引用本文复制引用
郑小东,罗键,罗义,魏成刚,刘榛榛..Ki-67预测乳腺癌对新辅助化疗反应的价值[J].川北医学院学报,2017,32(1):53-56,4.基金项目
南充市科技局项目(16YFZJ0021) （16YFZJ0021）
